Should all patients with duodenal adenocarcinoma be considered for aggressive surgical resection?

M. G. Hurtuk, S. Devata, K. M. Brown, K. Oshima, G. V. Aranha, J. Pickleman, M. Shoup

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Long-term survival for duodenal adenocarcinoma is inconsistent in the literature, and the biology of duodenal adenocarcinoma is poorly understood. Methods: One institution's experience with duodenal adenocarcinoma from 1984 to 2005 is reviewed. Clinicopathologic data were analyzed, and overall survival was estimated using Kaplan-Meier curves with log-rank test. Results: Of the 52 patients, 35 (67%) underwent potentially curative surgery; 31 survived the postoperative period and were included in the analysis. Of these, the median survival was 34 months (range 6 to 186 months) compared with 13 months (range 1 to 24 months) for those not undergoing curative surgery (P ≤ .001). Clinicopathologic factors favoring long-term survival were tumor size >3.5 cm (P ≤ .001) and T-stage ≤4 (P = .014). Conclusions: Clinicopathologic factors important to survival in duodenal cancer are T4 tumor status and tumor size. Interestingly, larger tumors were less likely to be invasive, and patients with these tumors had improved survival. The biology of this cancer is poorly understood; therefore, aggressive resection for all duodenal adenocarcinomas is recommended for all patients medically fit to undergo resection.

Original languageEnglish (US)
Pages (from-to)319-325
Number of pages7
JournalAmerican Journal of Surgery
Volume193
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Adenocarcinoma
Survival
Neoplasms
Duodenal Neoplasms
Postoperative Period

Keywords

  • Duodenal adenocarcinoma
  • Duodenum
  • Pancreas-sparing duodenectomy
  • Pancreaticoduodenectomy
  • Periampullary malignancy

ASJC Scopus subject areas

  • Surgery

Cite this

Hurtuk, M. G., Devata, S., Brown, K. M., Oshima, K., Aranha, G. V., Pickleman, J., & Shoup, M. (2007). Should all patients with duodenal adenocarcinoma be considered for aggressive surgical resection? American Journal of Surgery, 193(3), 319-325. https://doi.org/10.1016/j.amjsurg.2006.09.013

Should all patients with duodenal adenocarcinoma be considered for aggressive surgical resection? / Hurtuk, M. G.; Devata, S.; Brown, K. M.; Oshima, K.; Aranha, G. V.; Pickleman, J.; Shoup, M.

In: American Journal of Surgery, Vol. 193, No. 3, 03.2007, p. 319-325.

Research output: Contribution to journalArticle

Hurtuk, MG, Devata, S, Brown, KM, Oshima, K, Aranha, GV, Pickleman, J & Shoup, M 2007, 'Should all patients with duodenal adenocarcinoma be considered for aggressive surgical resection?', American Journal of Surgery, vol. 193, no. 3, pp. 319-325. https://doi.org/10.1016/j.amjsurg.2006.09.013
Hurtuk, M. G. ; Devata, S. ; Brown, K. M. ; Oshima, K. ; Aranha, G. V. ; Pickleman, J. ; Shoup, M. / Should all patients with duodenal adenocarcinoma be considered for aggressive surgical resection?. In: American Journal of Surgery. 2007 ; Vol. 193, No. 3. pp. 319-325.
@article{fe64c4dc969d4b5ca077fc6889d358fb,
title = "Should all patients with duodenal adenocarcinoma be considered for aggressive surgical resection?",
abstract = "Background: Long-term survival for duodenal adenocarcinoma is inconsistent in the literature, and the biology of duodenal adenocarcinoma is poorly understood. Methods: One institution's experience with duodenal adenocarcinoma from 1984 to 2005 is reviewed. Clinicopathologic data were analyzed, and overall survival was estimated using Kaplan-Meier curves with log-rank test. Results: Of the 52 patients, 35 (67{\%}) underwent potentially curative surgery; 31 survived the postoperative period and were included in the analysis. Of these, the median survival was 34 months (range 6 to 186 months) compared with 13 months (range 1 to 24 months) for those not undergoing curative surgery (P ≤ .001). Clinicopathologic factors favoring long-term survival were tumor size >3.5 cm (P ≤ .001) and T-stage ≤4 (P = .014). Conclusions: Clinicopathologic factors important to survival in duodenal cancer are T4 tumor status and tumor size. Interestingly, larger tumors were less likely to be invasive, and patients with these tumors had improved survival. The biology of this cancer is poorly understood; therefore, aggressive resection for all duodenal adenocarcinomas is recommended for all patients medically fit to undergo resection.",
keywords = "Duodenal adenocarcinoma, Duodenum, Pancreas-sparing duodenectomy, Pancreaticoduodenectomy, Periampullary malignancy",
author = "Hurtuk, {M. G.} and S. Devata and Brown, {K. M.} and K. Oshima and Aranha, {G. V.} and J. Pickleman and M. Shoup",
year = "2007",
month = "3",
doi = "10.1016/j.amjsurg.2006.09.013",
language = "English (US)",
volume = "193",
pages = "319--325",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Should all patients with duodenal adenocarcinoma be considered for aggressive surgical resection?

AU - Hurtuk, M. G.

AU - Devata, S.

AU - Brown, K. M.

AU - Oshima, K.

AU - Aranha, G. V.

AU - Pickleman, J.

AU - Shoup, M.

PY - 2007/3

Y1 - 2007/3

N2 - Background: Long-term survival for duodenal adenocarcinoma is inconsistent in the literature, and the biology of duodenal adenocarcinoma is poorly understood. Methods: One institution's experience with duodenal adenocarcinoma from 1984 to 2005 is reviewed. Clinicopathologic data were analyzed, and overall survival was estimated using Kaplan-Meier curves with log-rank test. Results: Of the 52 patients, 35 (67%) underwent potentially curative surgery; 31 survived the postoperative period and were included in the analysis. Of these, the median survival was 34 months (range 6 to 186 months) compared with 13 months (range 1 to 24 months) for those not undergoing curative surgery (P ≤ .001). Clinicopathologic factors favoring long-term survival were tumor size >3.5 cm (P ≤ .001) and T-stage ≤4 (P = .014). Conclusions: Clinicopathologic factors important to survival in duodenal cancer are T4 tumor status and tumor size. Interestingly, larger tumors were less likely to be invasive, and patients with these tumors had improved survival. The biology of this cancer is poorly understood; therefore, aggressive resection for all duodenal adenocarcinomas is recommended for all patients medically fit to undergo resection.

AB - Background: Long-term survival for duodenal adenocarcinoma is inconsistent in the literature, and the biology of duodenal adenocarcinoma is poorly understood. Methods: One institution's experience with duodenal adenocarcinoma from 1984 to 2005 is reviewed. Clinicopathologic data were analyzed, and overall survival was estimated using Kaplan-Meier curves with log-rank test. Results: Of the 52 patients, 35 (67%) underwent potentially curative surgery; 31 survived the postoperative period and were included in the analysis. Of these, the median survival was 34 months (range 6 to 186 months) compared with 13 months (range 1 to 24 months) for those not undergoing curative surgery (P ≤ .001). Clinicopathologic factors favoring long-term survival were tumor size >3.5 cm (P ≤ .001) and T-stage ≤4 (P = .014). Conclusions: Clinicopathologic factors important to survival in duodenal cancer are T4 tumor status and tumor size. Interestingly, larger tumors were less likely to be invasive, and patients with these tumors had improved survival. The biology of this cancer is poorly understood; therefore, aggressive resection for all duodenal adenocarcinomas is recommended for all patients medically fit to undergo resection.

KW - Duodenal adenocarcinoma

KW - Duodenum

KW - Pancreas-sparing duodenectomy

KW - Pancreaticoduodenectomy

KW - Periampullary malignancy

UR - http://www.scopus.com/inward/record.url?scp=33847076120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847076120&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2006.09.013

DO - 10.1016/j.amjsurg.2006.09.013

M3 - Article

C2 - 17320527

AN - SCOPUS:33847076120

VL - 193

SP - 319

EP - 325

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 3

ER -